Ucb Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?
UCB INC has forty-two approved drugs.
There are thirty-four US patents protecting UCB INC drugs.
There are four hundred and eighty-four patent family members on UCB INC drugs in fifty-one countries and thirty-nine supplementary protection certificates in fourteen countries.
Summary for Ucb Inc
International Patents: | 484 |
US Patents: | 34 |
Tradenames: | 29 |
Ingredients: | 24 |
NDAs: | 42 |
Drug Master File Entries: | 1 |
Patent Litigation for Ucb Inc: | See patent lawsuits for Ucb Inc |
Drugs and US Patents for Ucb Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ucb Inc | FINTEPLA | fenfluramine hydrochloride | SOLUTION;ORAL | 212102-001 | Jun 25, 2020 | RX | Yes | Yes | 11,759,440*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Ucb Inc | NAYZILAM | midazolam | SPRAY;NASAL | 211321-001 | May 17, 2019 | RX | Yes | Yes | 8,217,033 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Ucb Inc | BIPHETAMINE 12.5 | amphetamine resin complex; dextroamphetamine resin complex | CAPSULE, EXTENDED RELEASE;ORAL | 010093-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ucb Inc | VIMPAT | lacosamide | SOLUTION;INTRAVENOUS | 022254-001 | Oct 28, 2008 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ucb Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | 6,221,392 | ⤷ Try a Trial |
Ucb Inc | BRIVIACT | brivaracetam | SOLUTION;ORAL | 205838-001 | May 12, 2016 | 6,784,197 | ⤷ Try a Trial |
Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-002 | Oct 28, 2008 | RE38551 | ⤷ Try a Trial |
Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | 4,743,450 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Transdermal Film | 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr | ➤ Subscribe | 2013-11-26 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2012-10-29 |
➤ Subscribe | Injection | 10 mg/mL, 20 mL | ➤ Subscribe | 2016-06-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2005-12-27 |
➤ Subscribe | Tablets | 1000 mg | ➤ Subscribe | 2007-01-24 |
➤ Subscribe | Tablets | 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2012-10-29 |
➤ Subscribe | Extended-release Tablets | 1000 mg | ➤ Subscribe | 2011-01-07 |
➤ Subscribe | Tablets | 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg | ➤ Subscribe | 2004-01-15 |
International Patents for Ucb Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Germany | 05815688 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2010094535 | ⤷ Try a Trial |
Israel | 277505 | ⤷ Try a Trial |
Japan | 2022133279 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ucb Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0443983 | C00443983/03 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
0502314 | SPC/GB02/037 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
0480717 | 98C0025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0502314 | C300095 | Netherlands | ⤷ Try a Trial | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.